According to the data published by China Institute for the Control of Pharmaceutical and Biological Products, China Business News found that the inactivated hepatitis A vaccine produced by Beijing Kexing accounted for more than 53% of the domestic inactivated hepatitis A vaccine.
Injury vaccine production
On the evening of April 17, the production workshop of hepatitis A vaccine of Beijing Kexing Holding Products Co., Ltd. (hereinafter referred to as Beijing Kexing) located in Peking University Biological City, Haidian District, Beijing was closed down. The words on the seal read: "Seal of Chairman of Beijing Kexing Holding Products Co., Ltd.". Pan Aihua, chairman of Weiming Biomedical Co., Ltd. (hereinafter referred to as Weiming Pharmaceutical 00258 1), is currently the chairman of Beijing Kexing.
2065 438+06. 7. 8 Food and Drug Administration pointed out that vaccination is the most important, economical and effective means to prevent and control diseases. Food and drug supervision departments at all levels will cooperate with relevant departments to take effective measures to solve the problems existing in vaccine supply in time. Supervise vaccine production enterprises to organize production in strict accordance with the plan, and shall not arbitrarily reduce or stop production due to temporary sales difficulties, which will affect the normal supply and inoculation of vaccines.
The escalating privatization dispute
The reason behind the suspension of vaccine production is the privatization dispute of Beijing Kexing parent company Kexing Holdings (Hong Kong) Co., Ltd. (referred to as "Hong Kong Kexing").
Kexing Holdings is currently a vaccine manufacturer listed on the NASDAQ Global Select Market in the United States, and is also the only China vaccine manufacturer listed on the entire North American market. By the end of June 30, 2007, Kexing Holdings had achieved revenue of $66.908 million, gross profit of $59 1.73 million and net profit of $ 1.09 million.
The main production and operation entity of Kexing Holdings is Beijing Kexing.
Beijing Kexing was founded in 200 1, specializing in the research, development, production and sales of vaccines for human use. Shenkexing invested RMB 5 1 10,000 in the Monetary Fund, and Yin Weidong led his own R&D team; Team D (Tangshan Yi 'an) contributed 24 million yuan in intangible assets (the price of proprietary technology of inactivated hepatitis A vaccine), and Singapore Huading Biotechnology Co., Ltd. contributed 25 million yuan in cash. Yin Weidong was employed as the general manager of Beijing Kexing.
In 2002, Shenzhen Kexing transferred its controlling stake in Beijing Kexing to Weiming Group.
Since then, the shareholding structure of Beijing Kexing has changed many times, and the shareholding ratio of unnamed group has been decreasing. At present, Kexing Holdings holds 73.09% shares in Beijing Kexing through its subsidiary Hong Kong Kexing, and Weiming Group holds 26.95438+0% shares in Beijing Kexing through its subsidiary Weiming Medicine. However, Unnamed Medicine or Unnamed Group does not hold the shares of Kexing Holdings, an American listed company.
There is a huge market space for vaccines.
Beijing Kexing said that the company has inactivated hepatitis A vaccine, combined hepatitis A and hepatitis B vaccine, influenza vaccine (human avian influenza vaccine), the only preservative-free influenza virus split vaccine in China, influenza A vaccine H 1N 1 and inactivated enterovirus 7 1 (hereinafter referred to as EV7 1). In addition, the first phase I clinical study of inactivated SARS vaccine in the world was successfully developed and completed.
As far as EV7 1 is concerned, after the full implementation of the two-child policy, the number of newborns in China will reach17.5 million in 20 16 years. According to the vaccination rate of 30%, the market scale of EV7 1 can reach more than 2 billion yuan.
However, Kexing Holdings has been underestimated in the American capital market for a long time, and its financing function has not been reflected. Therefore, if we can privatize and return to A shares, on the one hand, we can improve the valuation, on the other hand, we can refinance to ensure the follow-up R&; Ampd and the expansion of company business
There are two key figures in the privatization of Kexing Holdings. One is Pan Aihua, the chairman of unnamed medicine who holds 26.9 1% shares in Beijing Kexing, and the other is Yin Weidong, the founder of Beijing Kexing, whose purchasing group holds 29.57% shares in Kexing Holdings.
20 16, Yin Weidong, chairman.
Because the buying group composed of Yin Weidong and Safran Fund holds the shares of Kexing Holdings and the number of board members of Kexing Holdings, unnamed medicine holds the shares of Beijing Kexing. Therefore, although the two purchasing groups are inevitable, they have been in a state of bidding and both have failed.
The bidding of unnamed medicine is also to promote the development of the enterprise itself.
According to the data, the core products of unnamed medicine are Enjingfu (mouse nerve growth factor for injection), Anfulong (recombinant human interferon 2b), Jeff (recombinant human interferon 2b spray), human vaccine and pharmaceutical intermediates.
"At present, the most profitable thing for unnamed medicine is Enjingfu. The sales in 20 16 was about 800 million yuan, and the sales in the first half of 20 17 was about 290 million yuan, but many other projects were not profitable. " A person familiar with the matter said.
20 17 was affected by the medical insurance control fee and the two-vote system, and the performance of unnamed medicine declined. In the unnamed pharmaceutical company gub, the director of the unnamed pharmaceutical company said in reply to the shareholders, "If the buyer group of the unnamed group is privatized successfully, Kexing plans to merge into the listed company."
On the evening of April 16, Weiming Pharmaceutical announced that Beijing Kexing Holding Products Co., Ltd., a wholly-owned subsidiary of Weiming Biomedical, refused to provide the company with the financial data and materials of Beijing Kexing 20 17, which also caused the audit institution hired by the company to be unable to attend the audit. The annual report of unnamed medicine 20 17 originally scheduled to be disclosed on April 24th, 20 18 was postponed to April 28th.
Kexing Holdings responded that "Beijing Kexing Holdings Products Co., Ltd., which holds 73.09% of the company's shares, has never refused to provide Beijing Kexing's financial data to Weiming Biomedical Co., Ltd., a shareholder of Beijing Kexing Holdings 26.9 1%.
The final result of privatization tug-of-war is still unclear.
Related questions and answers: Why did Beijing Kexing suspend the COVID-19 vaccination for people below 18 and the second dose of COVID-19 vaccination for people above 18?